Loading clinical trials...
Loading clinical trials...
A First-in-Human, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose, and Food-Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VNT-101 Administered Orally to Healthy Adult Participants
Conditions
Interventions
Placebo for VNT-101
VNT-101
Locations
1
United States
Altasciences Inc - Kansas City
Overland Park, Kansas, United States
Start Date
September 16, 2025
Primary Completion Date
November 1, 2026
Completion Date
November 1, 2026
Last Updated
April 17, 2026
NCT01386424
NCT07291635
NCT06599658
NCT06094010
NCT06753474
NCT06417762
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions